Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab

August 3, 2009 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

RTTNews -- Micromet, Inc., a biopharmaceutical company, Monday said its cancer drug Blinatumomab received Orphan Drug Designation status from the European Medicines Agency indicated in the treatment acute lymphoblastic leukemia.

Twitter
LinkedIn
Facebook
Email
Print

Clinical research Phase 2